Aoxiang Pharmaceutical's progress announcement on the repurchase of the company's shares through centralized bidding transactions
Securities code: 603229 Securities abbreviation: Aoxiang Pharmaceutical Announcement number: 2025-049
Zhejiang Aoxiang Pharmaceutical Co., Ltd.
Announcement on the progress of repurchasing the company's shares through centralized bidding transactions
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The first disclosure date of the repurchase plan is 2025/1/27
The implementation period of the buyback plan is 2025/1/24~2026/1/23
The estimated repurchase amount is 50 million yuan to 100 million yuan
□Reduce registered capital
√For equity incentives and/or employee stock ownership plans
Repurchase purpose
□Used to convert company convertible bonds
□To protect the company’s value and shareholders’ rights and interests
The cumulative number of shares repurchased is 5,201,200 shares
The cumulative number of shares repurchased accounts for 0.63% of the total share capital.
The cumulative repurchased amount is 50,006,023.36 yuan
The actual repurchase price range is 7.52 yuan/share~11.39 yuan/share
1. Basic information on share repurchase
Zhejiang Aoxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the sixth meeting of the fourth board of directors on January 24, 2025, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions", agreeing that the company will use its own funds and/or self-raised funds to repurchase some of the company's issued RMB ordinary shares (A shares) through centralized bidding transactions. The shares repurchased this time are planned to be used to implement equity incentives and/or employee stock ownership plans in the future. The total amount of funds for this repurchase shall not be less than RMB 50 million (inclusive) and shall not exceed RMB 100 million (inclusive). The repurchase price shall not exceed RMB 14/share (inclusive). The repurchase period shall be within 12 months from the date the company's board of directors considers and approves the share repurchase plan. For details, please refer to the "Aoxiang Pharmaceutical's Announcement on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions" (Announcement Number: 2025-002) and "Aoxiang Pharmaceutical's Repurchase Report on the Repurchase of Shares through Centralized Bidding Transactions" (Announcement Number: 2025-005) disclosed by the company on January 27, 2025 and February 6, 2025 respectively.
Due to the company's implementation of the annual equity distribution in 2024, starting from July 17, 2025, the upper limit of the share repurchase price will be adjusted from no more than RMB 14/share (inclusive) to no more than RMB 13.90/share (inclusive). For details, please refer to the "Aoxiang Pharmaceutical's Announcement on Adjusting the Repurchase Price Cap after the Implementation of the Equity Distribution in 2024" disclosed by the company on July 10, 2025 (Announcement Number: 2025-032).
2. Progress of share repurchase
In accordance with the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, the progress of the company's share repurchase is now announced as follows:
In October 2025, the company did not implement share repurchase.
As of October 31, 2025, the company has repurchased a total of 5,201,200 shares through centralized bidding transactions. The repurchased shares accounted for 0.63% of the company's total share capital. The highest transaction price was 11.39 yuan/share and the lowest price was 7.52 yuan/share. The total amount paid was 50,006,023.36 yuan (excluding transaction fees).
The above-mentioned share repurchase complies with the provisions of laws and regulations and the requirements of the company's share repurchase plan.
3. Other matters
The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions during the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Zhejiang Aoxiang Pharmaceutical Co., Ltd.
November 4, 2025